Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAC-001 in advanced solid tumors
NCT05399654Phase 2Active, not recruiting
- Sponsor
- Tallac Therapeutics
- Start
- Jun 2022
- Primary completion
- Jan 2026
- Modality
- Antisense DNA, Antibody Fragments, Small Interfering RNA (siRNA)
- Countries
- 2
01
Overview
Phase 2, open-label trial of TAC-001 in solid tumor (2 arms), sponsored by Tallac Therapeutics. Primary endpoints: Recommended Phase 2 Dose at 2 years, Overall Response Rate at 2 years and 2 more. Started Jun 2022; status: active, not recruiting.
02
Drugs
TAC-001
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05399654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05399654.